Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
leuprolide acetate
|
| gptkbp:administrativeDivision |
monthly
every three months |
| gptkbp:chemicalFormula |
gonadotropin-releasing hormone agonist
|
| gptkbp:clinicalTrials |
Phase II
Phase III Phase I hormonal therapy palliative treatment off-label use for gender dysphoria |
| gptkbp:contraindication |
pregnancy
thromboembolic events breastfeeding cardiovascular events osteoporosis hypersensitivity to leuprolide |
| gptkbp:date |
FDA_approved
|
| gptkbp:dosageForm |
injectable solution
30 mg 22.5 mg 7.5 mg |
| gptkbp:drugInterdiction |
anticoagulants
antidiabetic medications long-acting other hormonal therapies |
| gptkbp:endOfLife |
3 hours
extended release |
| gptkbp:formulation |
depot injection
|
| gptkbp:hasPopulation |
children
adults adolescents |
| gptkbp:healthcare |
important for efficacy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lupron Depot-PED
|
| gptkbp:is_monitored_by |
bone density
symptom relief hormone levels |
| gptkbp:lastProduced |
1990
|
| gptkbp:mandates |
prostate cancer
endometriosis central precocious puberty uterine fibroids |
| gptkbp:manufacturer |
AbbVie
|
| gptkbp:nutritionalValue |
hepatic
|
| gptkbp:route |
intramuscular injection
|
| gptkbp:sells |
gptkb:Lupron
|
| gptkbp:sideEffect |
nausea
headaches injection site reactions mood changes hot flashes |
| gptkbp:storage |
room temperature
protect from light |
| gptkbp:usedFor |
treatment of precocious puberty
|
| gptkbp:waterManagement |
urine
|